Written questions by Fortune.

Innovation and Technology, how much Government funding there was into psoriatic arthritis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into joint replacement research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government investment into vitamin D deficiency disease research there was in 2023-24; and which public bodies provided that investment.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into osteomalacia research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government investment into compression fracture research there was in 2023-24; and which public bodies provided that investment.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into reactive arthritis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into osteoporosis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Communities and Local Government, if she will make an assessment of the adequacy of the accessibility of the consultation entitled Reforming the Right to Buy, published on 20 November 2024.

The Government published the ‘Reforming the Right to Buy’ consultation via www.gov.uk on 20 November 2024, and is content that it meets the expected accessibility standards to allow all interested parties to contribute their views. As prescribed in the Government’s Publishing Accessible Documents guidance, the consultation is published in HTML format to make it easier to read and to find.It provides a variety of ways to respond to meet the range of accessibility needs; an online response option, a direct email address and a postal address for those unable to respond online. Anyone having any difficultly responding can get in touch using the contact details available to request assistance or an alternative way to respond.

If he will make an assessment of the adequacy of the accessibility of the consultation entitled Energy Company Obligation 4 and the Great British Insulation Scheme: mid-scheme changes, published on 14 November 2024.

Accessible versions of the Energy Company Obligation (ECO4) and Great British Insulation Scheme (GBIS) mid-scheme changes consultation (and all related documents) can be made available upon request at: https://www.gov.uk/government/consultations/energy-company-obligation-4-and-the-great-british-insulation-scheme-mid-scheme-changes Requestors are asked to submit a form to the relevant team to ensure accessibility requests are reasonable and proportionate.

If she will make an assessment of the adequacy of the accessibility of the consultation on Firefighters pensions: member contribution structure, published on 20 November 2024.

Accessible versions of both the consultation document and consultation questions document were published on 04/12/2024.These can be accessed at: Firefighters pensions: member contribution structure - GOV.UK

If she will make an assessment of the adequacy of the accessibility of the consultation on Police pensions: member contribution structure, published on 20 November 2024.

Accessible versions of both the consultation document and consultation questions document were published on 04/12/2024.These can be accessed at: Police pensions: member contribution structure - GOV.UK

Food and Rural Affairs, if he will make an assessment of the adequacy of the accessibility of the consultation entitled Open access restriction at Woodnook Valley (3), published on 20 November 2024.

Natural England (NE) is a relevant authority under the Countryside and Rights of Way Act 2000 for statutory restrictions and exclusions on access land. NE has a duty to publish a notice when it reviews these restrictions. NE uses existing Government websites for this purpose, posting a notification on GOV.UK that points to a Consultation Summary Report on Defra’s Citizen Space website. NE ensures its consultation information meets the accessibility requirements for these websites. The accessibility statement for the website is available here. This sets out what steps have been taken to make the website as accessible as possible. The accessibility statement for gov.uk is found here Accessibility statement for www.gov.uk - GOV.UK These are the pages for the consultations on Woodnook Valley and the Sandy Gulls and others restrictions: Open access restriction at Woodnook Valley (3): how to comment - GOV.UK Open access restriction at Woodnook Valley (case number 2005090101) - Defra - Citizen Space Open access restriction at Sandy Gulls and others: how to comment - GOV.UK Open access restriction at Sandy Gulls Trimingham House Beeston Regis and Laburnum camp and caravan parks (case numbers 2014117438 & 2014117440) - Defra - Citizen Space.

If she will make an assessment of the adequacy of the accessibility of the consultation on criminal justice joint inspection programme, published on 20 November 2024.

The Criminal Justice Joint inspectorates are consulting on their Criminal Justice Joint Inspection Programme. This consultation is published online and available in both HTML and PDF formats.This is a public consultation intended to gather the views of those with experience of the criminal justice system to ensure the most pertinent issues are inspected.Where accessibility issues arise, the secretariat for the programme is able to provide alternative formats for the consultation document.Details of this are available on gov.uk: https://www.gov.uk/government/consultations/consultation-on-criminal-justice-joint-inspection-programme

Food and Rural Affairs, if he will make an assessment of the adequacy of the accessibility of the consultation on Open access restriction at Sandy Gulls and others: how to comment, published on 22 November 2024.

Natural England (NE) is a relevant authority under the Countryside and Rights of Way Act 2000 for statutory restrictions and exclusions on access land. NE has a duty to publish a notice when it reviews these restrictions. NE uses existing Government websites for this purpose, posting a notification on GOV.UK that points to a Consultation Summary Report on Defra’s Citizen Space website. NE ensures its consultation information meets the accessibility requirements for these websites. The accessibility statement for the website is available here. This sets out what steps have been taken to make the website as accessible as possible. The accessibility statement for gov.uk is found here Accessibility statement for www.gov.uk - GOV.UK These are the pages for the consultations on Woodnook Valley and the Sandy Gulls and others restrictions: Open access restriction at Woodnook Valley (3): how to comment - GOV.UK Open access restriction at Woodnook Valley (case number 2005090101) - Defra - Citizen Space Open access restriction at Sandy Gulls and others: how to comment - GOV.UK Open access restriction at Sandy Gulls Trimingham House Beeston Regis and Laburnum camp and caravan parks (case numbers 2014117438 & 2014117440) - Defra - Citizen Space.

If he will make an assessment of the adequacy of the accessibility of the consultation on the implementation of the new subscription contracts regime, published on 18 November 2024.

The consultation on the implementation of the subscription contracts follows the UK Government Consultation principles (Consultation principles: guidance - GOV.UK). The subscription consultation is available in HTML and PDF formats. HTML provides greater accessibility for users. The PDF was published as an accessible PDF. Alternative methods of completing the consultation are available including online, via email and via post.

Food and Rural Affairs, if he will make an assessment of the adequacy of the accessibility of the consultation entitled ICES area 7d and Lyme Bay king scallop dredge fishery closure 2025, published on 18 November 2024.

The Marine Management Organisation (MMO) works closely with the fishing industry and other stakeholders and understands the need for information to be put to them in a manner that allows them to contribute meaningfully to Government consultations. Management of the king scallop fishery in the English Channel is an annual consultation and MMO listens and responds to how the consultation was received and amends its processes for the consultation the following year. To ensure that there is a balance between simple and technical language to meet the needs of the reader, The document has been developed with the essential information in straightforward language at the start of the document and the more technical information following for those that want the detail. MMO will provide the consultation material in different formats on request, and it has been provided in person and in video format previously. We have included the invitation to utilise alternative formats in supporting communication material. The annual consultation is accompanied by a communications plan that sees officials engaging face to face with representative industry groups and individual fishers in relevant fishing ports.

If he will make an assessment of the adequacy of the accessibility of the Change.NHS.UK consultation, published on 24 October 2024.

On 21 October we launched the biggest ever national conversation on the future of the National Health Service. We are putting the public and staff at the centre of the policy making process. We have designed this engagement to make sure as many people as possible from all communities and backgrounds are supported to contribute their views. This is being done through the change.NHS.UK website, and through online and in-person events across England.The change.NHS.UK website provides a variety of formats and ways to respond, for a range of accessibility needs. This includes British Sign Language (BSL) and easy-read formats of the surveys, and the option to respond by post, email, telephone, or BSL video. There is a dedicated accessibility page on the website that signposts to these formats and the alternative ways to respond, as well as contact details for any further support. We were made aware of some digital accessibility issues on the website, and the majority of the issues are now resolved. Further detail is set out in the accessibility statement on the change.NHS.UK website.

Communities and Local Government, what assessment she has made of the adequacy of the accessibility of the consultation on ending Pan-Regional Partnership core funding.

At the Autumn Statement, the government announced its intention to end core funding for Pan-Regional Partnerships and consult on the impacts of this decision, if it were taken forward. This public consultation is now live and accessible on Gov.uk and Government will consider all responses received by the deadline of Monday 16th December.

If he will make an assessment of the adequacy of the accessibility of the consultation on Tackling modern slavery in NHS procurement: proposed regulations and guidance, published on 21 November 2024.

The consultation document is available in an accessible format, on the GOV.UK website, at the following link:https://www.gov.uk/government/consultations/tackling-modern-slavery-in-nhs-procurement-proposed-regulations-and-guidance/tackling-modern-slavery-in-nhs-procurement-proposed-regulations-and-guidanceIt is alongside a digital survey, also hosted on an accessible platform, for users to respond to the consultation.

Food and Rural Affairs, if he will make an assessment of the adequacy of the accessibility of the consultation on Draft information and guidance on storm overflows, published on 21 November 2024.

On the 21 of November, Defra launched a two-month consultation on updated technical guidance on storm overflows in England. Defra are looking for feedback from water companies, trade bodies, environmental non-government organisations and other key stakeholders including industry groups, research institutes, and engineering and environmental management organisations. As this is technical guidance on the management of storm overflows in England, we have targeted the consultation at water and sewerage companies, trade bodies and around 30 environmental non-governmental organisations. More information can be found on the GOV.UK page for the consultation.